Pierre Legault
Independent DirectorMr. Pierre Legault, CA, MBA, CPA, BAA, is Chairman of the Board at Amolyt Pharma SAS and Sitryx Therapeutics from March 24, 2021. He serves as the Board Chairman at Sitryx Therapeutics Limited. He had been a Director of Clementia Pharmaceuticals Inc. since January 30, 2018. Mr. Legault served as Director of Iroko Pharmaceuticals, LLC since April 1, 2015. He serves as an Independent Director at Syndax Pharmaceuticals, Inc. since January 5, 2017. He served as the Director of Adynxx, Inc since May 3, 2019 until July 19, 2019. He was Chairman of the Board at Bicycle Therapeutics Ltd since March 15, 2019 until June 17, 2025. He served as the Chief Executive Officer of NephroGenex, Inc. from 2014 to April 13, 2016 and served as its Chairman from 2012 to 2013 and served as its President from September 1, 2015 to April 13, 2016. Mr. Legault joined NephroGenex, Inc. in October 2013. He served as the Chief Financial Officer, Executive Vice President and Treasurer of OSI Pharmaceuticals Inc. since December 29, 2008 until January 2011 and served as its Principal Accounting Officer. He served as Chief Executive Officer of Prosidion, Ltd. since 2010 until 2012. He served as the President US of Brooks Eckerd. He served as President of the Eckerd Group. He served as the Senior Vice President of Finance, Information System & E-business and Chief Financial Officer of Sanofi US Services Inc. (sanofi-aventis U.S. Inc. (Aventis Pharmaceuticals Inc.). From January 2006 to December 2008, he worked for Rite Aid Corporation. He served as the Chief Administrative Officer and Senior Executive Vice President of Rite Aid Corp. from June 2007 to September 2008 and served as its Senior Vice President since June 2007. He served as an Executive Vice President of The Jean Coutu Group (PJC) Inc. from January 15, 2006 to March 2007. He served several senior positions at Sanofi-Aventis and predecessor companies over a period of 16 years, last serving in the position of President of the Global Dermatology division of Sanofi-Aventis Group until December 2005. He served as Worldwide President of a large, global dermatology business unit. He has held senior management positions at Eckerd and Sanofi-Aventis. Mr. Legault served as the Chief Financial Officer and Senior Vice President of the North American business of Aventis from 2000 to 2003, Global Senior Vice-President of Finance and Treasury of Hoechst Marion Roussel, Inc. from 1998 to 2000, Chief Financial Officer, Chief Information Officer and Vice President of North America Finance, Information Services and Administration of Marion Merrell Dow, Inc. from 1997 to 1998 and Chief Financial Officer (Finance, Information Systems and Administration) and Vice President of Marion Merrell Dow Pharmaceutical Canada from 1990 to 1996. He has significant experience served on the Board of Directors of public companies. Mr. Legault has also served as a Director and as Chairman of Bicycles Therapeutics Inc. since March 2019, served as a Director and as Chairman of Amolyt Pharmaceuticals Inc. since April 2020. He was Chairman of Poxel SA since March 31, 2016 until March, 2023. He had been an Independent Director of Urovant Sciences Ltd. since July 2018 until March 29, 2021 and its Lead Independent Director since December 2019 until March 29, 2021. He has been an Independent Director of Poxel SA since January 29, 2016. He has been Chairman at Poxel Pharmaceuticals. He served as Chairman of Artios Pharma Limited until April 2025. He was a Director at ARMO Biosciences Inc. since April 2017 until June 22, 2018. He serves as a Director of OSI Investment Holdings GMBH. He served as a Director of Regado Biosciences, Inc. since November 18, 2013. He served as a Director of NPS Pharmaceuticals, Inc. from November 2014 to February 21, 2015. He served as an Independent Director of Tobira Therapeutics, Inc. from November 2013 to November 1, 2016. He served as an Independent Director of Forest Laboratories, Inc. since 2012. He served as a Non-Executive Director of Cyclacel Pharmaceuticals, Inc. from March 9, 2007 to March 17, 2009. He served as a Director of The Jean Coutu Group (PJC) Inc., since August 2004. He serves as a Board Member of the Finance Executive Institute and the Canadian Institute of Chartered Accountants. Mr. Legault is a Member of the U.S. Certified Public Accounting Association. He studied MBA in Marketing at McGill University in the year 2005 to 2009, Mr. Legault earned a B.B.A. in Business & International Finance from HEC Montreal and also graduated at the Harvard Business School and holds a Six Sigma Green Belt and holds Chartered Accountant and Certified Public Accountant diploma.
Positions
- Company NameSyndax Pharmaceuticals, Inc.Stock CodeSNDXPositionIndependent DirectorColleagues
- MAMichael A. MetzgerCEO & Director
- DGDennis G. PodlesakIndependent Chairman
- LJLuke J. AlbrechtGeneral Counsel & Corporate Secretary
- KAKeith Alan GoldanExecutive Officer
- SCSteven ClosterChief Commercial Officer
- NANicholas A.J. BotwoodHead of Research & Development and Chief Medical Officer
- KAKeith A. KatkinIndependent Director
- JAJennifer A. JarrettIndependent Director
